ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1540

Cardiovascular Risk Management in Rheumatoid Arthritis Patients

Calin Popa1, Elke.E.A. Arts1, Inger L. Meek1, Frank H.J. van den Hoogen2 and Jaap Fransen1, 1Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Cardiovascular disease and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) patients have been previously shown to have a higher cardiovascular (CV) burden as compared to the general population. The CV risk in RA seems still underestimated. We present here the results of a 1.5 year experience of our Department with the CV risk management in RA patients. 

Methods: RA patients have been consecutively screened on lipid profile and blood pressure. Other CV risk factors have been also recorded (smoking, CV history, family history of premature atherosclerotic events, weight –BMI, renal function, glucose). Patients fulfilled either the 1987 ACR criteria or the revised ACR-EULAR criteria for the diagnosis of RA. They were visiting the outpatient clinic for their regular controls. The SCORE index has been used to determine their 10-year risk to develop CV event/ death by CV event.  

Results: In total, 342 RA patients have been consecutively screened. Among them 181 patients have been tested in primary prevention setting and were further analyzed (Table 1). Forty patients (22%) had hypertension. Thirty-three patients (18%) should have been treated with statins according to their 10-years CV risk as calculated using the algorithms for the general population. This percentage almost tripled (52%) if CBO recommendations for RA patients have been applied. Finally, 17% of the studied group had a high CV risk according to SCORE index for the general population, increasing to 21% according to SCORE-EULAR and to 49% when CBO guidelines recommendations for RA patients have been applied (Table 2). 

Conclusion: There is a relative high percentage of RA patients in need for primary prevention measures, yet the use of SCORE-CBO might easily overestimate/exaggerate the risk. Screening for CV risk factors early in the course of disease should be integrated in the standards protocols for RA management. Applying the “treat to target” strategy together with primary prevention measures might drastically reduce CV burden in RA in the near future. 

 

Primary prevention (N=181)

Age (years)

56 ± 14

Gender (M:F)

70:111

Disease duration (years)

10 ± 8

Rheumatoid factor (% positive)

73 (%)

BMI (kg/m²)

25 ± 4

Total cholesterol (mmol/l)

5.41 ± 1.03

HDL (mmol/l)

1.38 ± 0.34

TC:HDL

4.11 ± 1.14

Systolic blood pressure (mmHg)

127 ± 16

Diastolic blood pressure (mmHg)

76 ± 10

Smokers (%)

23 (%)

Table 1. Main characteristics of the RA group in which the screening has been applied in the primary prevention setting (mean ± SD); BMI = body mass index; HDL = high-density lipoprotein; TC = total cholesterol; 

 

SCORE

SCORE-EULAR

SCORE-CBO

Low risk (<10%)

124

113

57

Intermediate risk (10-19)

25

29

36

High risk (>20%)

32

39

88

Table 2. Distribution of CV risk among the 181 RA patients. SCORE-EULAR = SCORE index according to EULAR recommendations (x 1.5 when two of the following factors have been present: rheumatoid factor, disease duration> 10 years, extra-articular manifestations); EULAR-CBO = SCORE according to 2011 CBO guidelines ( adding 15 years to current age)


Disclosure: C. Popa, None; E. E. A. Arts, None; I. L. Meek, None; F. H. J. van den Hoogen, None; J. Fransen, None.

To cite this abstract in AMA style:

Popa C, Arts EEA, Meek IL, van den Hoogen FHJ, Fransen J. Cardiovascular Risk Management in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/cardiovascular-risk-management-in-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-risk-management-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology